Literature DB >> 9467183

Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats.

S Verma1, S Bhanot, E Arikawa, L Yao, J H McNeill.   

Abstract

Effects of pioglitazone on plasma insulin levels, systolic blood pressure and arterial reactivity were studied in spontaneously hypertensive (SH) rats. Chronic treatment of SH rats with pioglitazone decreased plasma insulin levels and blood pressure. Direct effects of pioglitazone on vascular reactivity were also studied in aortae and superior mesenteric arteries from SH rats. Pioglitazone markedly inhibited arginine vasopressin (AVP) and norepinephrine (NE) responses without affecting responses to potassium chloride (KCl). These data suggest that (a) antihypertensive effects of pioglitazone in SH rats may be mediated via a direct vasodepressor effect, and (b) vasodilation may be coupled to insulin sensitivity in SH rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467183     DOI: 10.1159/000028177

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

Review 1.  Pioglitazone.

Authors:  P S Gillies; C J Dunn
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

2.  Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.

Authors:  L C Pickavance; M Tadayyon; P S Widdowson; R E Buckingham; J P Wilding
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection.

Authors:  William G Sanders; Huan Li; Ilya Zhuplatov; Yuxia He; Seong-Eun Kim; Alfred K Cheung; Jayant Agarwal; Christi M Terry
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

4.  A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.

Authors:  Kevin B Atkins; Brittany Irey; Nan Xiang; Frank C Brosius
Journal:  Am J Physiol Cell Physiol       Date:  2009-03-04       Impact factor: 4.249

5.  Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human.

Authors:  Osamu Ito; Yasuhiro Nakamura; Liping Tan; Tsuneo Ishizuka; Yuko Sasaki; Naoyoshi Minami; Masayuki Kanazawa; Sadayoshi Ito; Hironobu Sasano; Masahiro Kohzuki
Journal:  Mol Cell Biochem       Date:  2006-03-22       Impact factor: 3.396

6.  Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.

Authors:  S Takatori; Y Zamami; N Yabumae; N Hanafusa; M Mio; T Egawa; H Kawasaki
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

Review 7.  Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.

Authors:  Bodh I Jugdutt
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

8.  Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats.

Authors:  Mohammad M Naderali; Imose Itua; Abdul-Razak Abubakari; Ebrahim K Naderali
Journal:  ISRN Pharmacol       Date:  2012-08-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.